ArticleInternational journal of biological macromolecules2025
Structural and epitope characterization of anti-DEFA5 monoclonal antibodies clones 1A8 and 4F5 for inflammatory bowel disease subtype diagnostics.
Article in International journal of biological macromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Understanding antigen-antibody interactions is key to advancing immunodiagnostics and therapeutic development. Here, we characterize two mouse monoclonal antibodies, 1A8 and 4F5, specific to human DEFA5, an innate immune effector implicated in differentiating colonic inflammatory bowel disease (IBD) subtypes, particularly Ulcerative colitis, Crohn's colitis and Indeterminate colitis. Although both antibodies target similar regions of DEFA5, they exhibit distinct binding affinities. Hydrogen/deuterium exchange mass spectrometry (HDX-MS) revealed diffuse protection patterns with partial protection upon antibody binding, suggesting conformational stabilization in DEFA5 rather than discrete epitope recognition. Complementary peptide-based epitope mapping confirmed localized linear or semi conformational binding epitopes. Surface Plasmon Resonance (SPR) confirmed 1:1 binding stoichiometry and high-affinity binding of both antibodies for the DEFA5 epitope RATCYCRTGRCAT. Hybridoma sequencing revealed that both antibodies engage DEFA5 by an extended binding interface involving multiple complementarity-determining regions (CDRs) across both heavy and light chains, indicating structurally distributed mode of antigen recognition. Despite identical hybridoma sequencing, HADDOCK models reveal subtle binding pose differences with DEFA5 engages the VH domain in 1A8, while it interacts with the VL domain in 4F5, suggesting phenotypic variations in domain contributions. This integrative approach provides mechanistic insights into their diagnostic potential for distinguishing IBD subtypes, supporting refined tissue-based and serological assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.